Article Figures & Data
Figures
- Fig. 1.
Molecular structure of EXE and 17-H-EXE.
- Fig. 2.
BMD of the lumbar spine after 16 weeks of treatment with EXE, 17-H-EXE, and LET. Scale bars represent the mean ± SE (n = 12). ∗, P < 0.005 versus OVX controls.
- Fig. 3.
BMD of the femora after 16 weeks of treatment with EXE, 17-H-EXE, and LET. Scale bars represent the mean ± SE (n = 12). ∗, P < 0.05 versus OVX controls.
- Fig. 4.
Serum PYD levels after 16 weeks of treatment with EXE, 17-H-EXE, and LET. Scale bars represent the mean ± SE (n = 12). ∗, P < 0.001 versus OVX controls.
- Fig. 5.
Serum OC levels after 16 weeks of treatment with EXE, 17-H-EXE, and LET. Scale bars represent the mean ± SE (n = 12). ∗, P < 0.05 versus OVX controls.
- Fig. 6.
Three-point bending strength of the femora after 16 weeks of treatment with EXE, 17-H-EXE, and LET. Scale bars represent the mean ± SE (n = 12). ∗, P < 0.01 versus OVX controls.
- Fig. 7.
Compressive strength of the fifth lumbar vertebrae after 16 weeks of treatment with EXE, 17-H-EXE, and LET. Scale bars represent the mean ± SE (n = 12). ∗, P < 0.05 versus OVX controls.
- Fig. 8.
Serum cholesterol levels after 16 weeks of treatment with EXE, 17-H-EXE, and LET. Scale bars represent the mean ± SE (n = 12). ∗, P < 0.005 versus OVX controls.
- Fig. 9.
Serum LDL levels after 16 weeks of treatment with EXE, 17-H-EXE, and LET. Scale bars represent the mean ± SE (n = 12). ∗, P < 0.05 versus OVX controls.
Tables
- Table 1
Histomorphometric measures
Group BV (%) Md.V (%) Tb.N (mm−1) Tb.Sp (μm) Tb.Th (μm) OV (%) OS (%) O.Th (μm) ES (%) Intact 16.93 ± 0.23 16.88 ± 0.24 2.83 ± 0.07 294.9 ± 8.0 60.02 ± 1.06 0.28 ± 0.05 3.85 ± 0.60 2.18 ± 0.13* 1.05 ± 0.25† OVX 10.49 ± 0.78‡ 10.11 ± 0.75‡ 1.80 ± 0.09‡ 502.3 ± 27.2‡ 58.03 ± 2.29 3.52 ± 0.64‡ 20.86 ± 2.62‡ 4.89 ± 0.58 2.73 ± 0.63 OVX + EXE (20 mg/kg) 13.44 ± 0.67 13.52 ± 0.59 2.12 ± 0.10 411.8 ± 19.6 64.27 ± 1.33 0.77 ± 0.11 6.83 ± 0.86 4.03 ± 0.61 1.72 ± 0.61 OVX + EXE (50 mg/kg) 17.92 ± 0.90 17.84 ± 0.90 3.00 ± 0.17 277.8 ± 18.8 59.83 ± 0.73 0.43 ± 0.05 4.09 ± 0.62 3.32 ± 0.26* 1.11 ± 0.27† OVX + EXE (100 mg/kg) 17.09 ± 1.11 17.04 ± 1.10 2.89 ± 0.14 289.7 ± 17.4 59.09 ± 2.69 0.31 ± 0.02 3.58 ± 0.33 2.81 ± 0.47* 1.02 ± 0.24† OVX +17-H-EXE (20 mg/kg) 17.64 ± 0.92 17.56 ± 0.91 2.69 ± 0.16 311.72 ± 21.1 66.21 ± 3.92 0.40 ± 0.08 4.09 ± 0.51 3.27 ± 0.38* 1.14 ± 0.21† -
NOTE. Data are mean ± SE (n = 5).
-
Abbreviations: BV, bone volume; Md.V, mineralized trabecular bone volume; Tb.N, trabecular number; Tb.Sp, trabecular separation; Tb.Th, trabecular thickness; OV, osteoid volume; OS, osteoid surface; O.Th, osteoid thickness; ES, eroded surface.
-
* P < 0.005 versus OVX rats.
-
† P < 0.05 versus OVX rats.
-
‡ Significant difference from all other groups (P< 0.001).
-
- Table 2
Serum HDL and triglyceride levels
Group HDL (mmol/L) Triglycerides (mmol/L) Intact (i.m.) 2.29 ± 0.06a 0.55 ± 0.03 OVX (i.m.) 2.65 ± 0.10 0.83 ± 0.07 OVX + EXE (20 mg/kg) 2.56 ± 0.08 0.77 ± 0.04 OVX + EXE (50 mg/kg) 1.82 ± 0.04a 0.87 ± 0.07 OVX + EXE (100 mg/kg) 1.64 ± 0.06a 0.71 ± 0.04 OVX +17-H-EXE (20 mg/kg) 2.04 ± 0.11a 0.91 ± 0.05 Intact (p.o.) 2.40 ± 0.09 0.70 ± 0.08 OVX (p.o.) 2.29 ± 0.08 0.67 ± 0.06 OVX + LET (1 mg/kg) 2.54 ± 0.06 0.87 ± 0.04 -
NOTE. Data are mean ± SE (n = 12).
-
Abbreviations: i.m., intramuscular injection; p.o., oral gavage.
-
* P < 0.001 versus OVX (i.m.) controls.
-
Volume 10, Issue 17
